<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045679</url>
  </required_header>
  <id_info>
    <org_study_id>FF 74/2016</org_study_id>
    <nct_id>NCT03045679</nct_id>
  </id_info>
  <brief_title>One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass</brief_title>
  <acronym>MGBvsRYGB</acronym>
  <official_title>The Evidence of One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass in Metabolic Surgery - a Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sana Klinikum Offenbach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sana Klinikum Offenbach</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective randomized controlled trial is to compare the two procedures
      One-anastomosis gastric Bypass/Mini-gastric Bypass (OAGB/MGB) and Roux-en Y gastric bypass
      (RYGB) in relation to intraoperative and postoperative complications (classification of
      Clavien-Dindo), mortality, metabolic impact (remission of type 2 diabetes mellitus,
      hypertonus, gastro-esophageal reflux disease, sleep apnea, dyslipidemia, quality of life,
      operation time, postoperative excess weight loss, malnutrition and re-do/revisonal surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OAGB/MGB is gaining popularity as a primary surgical treatment for morbid obesity due to
      reduced operation time, a shorter learning curve, better weight loss, higher metabolic impact
      and fewer major complications compared to RYGB.

      In this prospective randomized controlled trial we want to compare OAGB/MGB and RYGB with a
      FU of up to 24 month.

      Patients with indication for gastric bypass get randomized in group A (RYGB, n = 50) or B
      (OAGB/MGB, n = 50). FU is performed 1, 3, 6, 12 and 24 month after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomized controlled trial: RYGB (group A) vs OAGB/MGB (group B)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>envelope randomization</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>complications</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>complications classified next to Clavien-Dindo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>death up to 2 years after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission of type 2 diabetes mellitus</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>HbA1c &lt; 6.5% without medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission of hypertonus</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>blood pressure &lt; 140/90 mmHg without medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastro-esophageal reflux disease</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>GERD-HRGL Heartburn Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission of sleep apnea</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>presence/absence of CPAP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission of hypertrigliceridemia</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>triglyceride &lt; 200mg/dl without medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>remission of hypercholesterinemia</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>cholesterin &lt; 155 mg/dl without medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life questionnaire</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>changing in quality of life measured by questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative excess weight loss in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operation time</measure>
    <time_frame>operation time during surgery in minutes</time_frame>
    <description>operation time during surgery in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 1</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: protein &lt; 64 g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 2</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: albumin &lt; 35 g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 3</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: ferritin (&lt; 30 µg/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 4</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: vitamin E &lt; 12 µmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 5</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: vitamin K &lt; 90 ng/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 6</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: vitamin 25-OH- Vitamin D3 &lt; 50 nmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 7</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: vitamin A &lt; 1.05 µmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malnutrition 8</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>postoperative malnutrition: vitamin B12 &lt; 145 pmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>revisional surgery</measure>
    <time_frame>up to 2 years after surgery</time_frame>
    <description>revisional surgery during follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OAGB/MGB-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RYGB</intervention_name>
    <description>laparoscopic RYGB</description>
    <arm_group_label>RYGB-group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OAGB/MGB</intervention_name>
    <description>laparoscopic OAGB/MGB</description>
    <arm_group_label>OAGB/MGB-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. primary obesity surgery and indication for gastric bypass

          2. age: 18 - 65 years

          3. BMI &gt; 40 kg/m² or BMI &gt; 35 kg/m² with obesity related comorbidities

          4. informed consent

        Exclusion Criteria:

          1. obesity surgery in the anamnesis

          2. visceral surgery in the anamnesis (excluding appendectomy and cholecystectomy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Chiappetta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sana Klinikum Offenbach</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sonja Chiappetta, MD</last_name>
    <phone>0049 69 8405 1700</phone>
    <email>sonja1002@gmx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sana Klinikum Offenbach</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63069</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonja Chiappetta, MD</last_name>
      <phone>00496984051706</phone>
      <email>sonja1002@gmx.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Chevallier JM, Arman GA, Guenzi M, Rau C, Bruzzi M, Beaupel N, Zinzindohoué F, Berger A. One thousand single anastomosis (omega loop) gastric bypasses to treat morbid obesity in a 7-year period: outcomes show few complications and good efficacy. Obes Surg. 2015 Jun;25(6):951-8. doi: 10.1007/s11695-014-1552-z.</citation>
    <PMID>25585612</PMID>
  </results_reference>
  <results_reference>
    <citation>Jammu GS, Sharma R. A 7-Year Clinical Audit of 1107 Cases Comparing Sleeve Gastrectomy, Roux-En-Y Gastric Bypass, and Mini-Gastric Bypass, to Determine an Effective and Safe Bariatric and Metabolic Procedure. Obes Surg. 2016 May;26(5):926-32. doi: 10.1007/s11695-015-1869-2.</citation>
    <PMID>26337694</PMID>
  </results_reference>
  <results_reference>
    <citation>Musella M, Apers J, Rheinwalt K, Ribeiro R, Manno E, Greco F, Čierny M, Milone M, Di Stefano C, Guler S, Van Lessen IM, Guerra A, Maglio MN, Bonfanti R, Novotna R, Coretti G, Piazza L. Efficacy of Bariatric Surgery in Type 2 Diabetes Mellitus Remission: the Role of Mini Gastric Bypass/One Anastomosis Gastric Bypass and Sleeve Gastrectomy at 1 Year of Follow-up. A European survey. Obes Surg. 2016 May;26(5):933-40. doi: 10.1007/s11695-015-1865-6.</citation>
    <PMID>26341086</PMID>
  </results_reference>
  <results_reference>
    <citation>Guenzi M, Arman G, Rau C, Cordun C, Moszkowicz D, Voron T, Chevallier JM. Remission of type 2 diabetes after omega loop gastric bypass for morbid obesity. Surg Endosc. 2015 Sep;29(9):2669-74. doi: 10.1007/s00464-014-3987-7. Epub 2015 Jan 1.</citation>
    <PMID>25552228</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee WJ, Yu PJ, Wang W, Chen TC, Wei PL, Huang MT. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg. 2005 Jul;242(1):20-8.</citation>
    <PMID>15973097</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2017</study_first_submitted>
  <study_first_submitted_qc>February 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sana Klinikum Offenbach</investigator_affiliation>
    <investigator_full_name>Sonja Chiappetta, MD</investigator_full_name>
    <investigator_title>Principal investigator: Dr. Sonja Chiappetta</investigator_title>
  </responsible_party>
  <keyword>Roux-en Y gastric bypass</keyword>
  <keyword>One-anastomosis gastric bypass</keyword>
  <keyword>Mini-gastric bypass</keyword>
  <keyword>metabolic surgery</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

